INTRODUCTION
Frontotemporal dementia (FTD) classically affects adults in their fifties to sixties, although cases have been reported in patients from 30 to more than 90 years of age. FTD is a progressive neurodegenerative disorder; thus, the patient's history typically reveals a gradual onset and progression of changes in behavior or language deficits for several years prior to presentation to a neurologist. The term FTD is typically used to refer to one of several clinical subtypes including behavioral variant of FTD (bvFTD), semantic variant primary progressive aphasia (PPA), nonfluent agrammatic variant PPA, and FTD associated with motor neuron disease (FTD-MND). FTDrelated disorders include two tauassociated neurodegenerative diseases, corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), which can present with frontal lobe dysfunction. The clinical subtypes of FTD and related disorders are defined by the hallmark patterns of symptoms and signs observed. Variations in clinical presentation across the FTD subtypes are attributed to differences in the brain regions affected by FTD pathology. The term frontotemporal lobar degeneration (FTLD) is reserved for patients with clinical presentations of FTD and identification of an FTD-causing mutation or histopathologic evidence of FTD (on biopsy or postmortem). early-onset neurodegenerative dementia (before age 65) , second only to Alzheimer disease (AD). 1 The estimated prevalence of FTD is highest in the 45 to 64 year age group and ranges from 15 to 22 per 100,000 persons ages 45 to 64, with 10% of FTD occurring in patients less than 45 years of age and approximately 30% occurring in patients older than 65. 1 There is consensus that the prevalence is likely underestimated due to lack of recognition and diagnosis of the FTD syndromes by nonneurologists. 1, 2 Of the FTD subtypes, bvFTD is the most common clinical presentation, accounting for more than 50% of patients with autopsyconfirmed FTLD. 3 FTD affects both genders in roughly equal distribution.
BEHAVIORAL VARIANT OF FRONTOTEMPORAL DEMENTIA bvFTD is defined by the gradual onset and progression of changes in behavior, including disinhibition, loss of empathy, apathy, and may include hyperorality and perseverative or compulsive behaviors ( Table 5-1) . 4 Patients presenting with symptoms consistent with bvFTD but with normal brain imaging (ie, CT, MRI, positron emission tomography [PET]/single-photon emission computed tomography [SPECT]) are classified as possible bvFTD, while patients meeting symptom criteria who show focal atrophy, hypometabolism, or hypoperfusion in the frontal or temporal lobes are classified as having probable bvFTD.
Symptoms
Disinhibition may manifest in a variety of ways, including increased disclosure of personal information to strangers or acquaintances (eg, medical information, finances), increased sexual interest or comments, loss of manners (such as belching in public), new use of derogatory or racist language in reference to others (eg, calling someone fat or bald in public), and impulsivity (eg, inappropriate spending). Apathy is a common early feature and may present as a loss of interest in usual social and nonsocial activities. Patients may be noted to spend hours sitting on the couch staring at the television or wall. Some patients will develop simple or complex repetitive behaviors such as touching items in a room, counting figures on patterned wallpaper, or picking up scraps of paper in public places. Hyperorality typically involves increased consumption, particularly of sweets, and in the extreme, can include consumption of spoiled foods and inedible objects. Some patients will begin to use tobacco or alcohol for the first time or increase their use of such substances. Although not included in the core criteria, patients with FTD, particularly those with C9ORF72 expanded repeat mutations, may also exhibit psychotic features early in the disease course, including visual or auditory hallucinations and bizarre or somatic delusions. 5 Neurologic Examination Evidence of the above behavioral changes may be observed during the course of the neurologic examination. Patients with bvFTD may show evidence of poor grooming and hygiene on presentation and loss of manners, such as belching during the examination. Either a flat affect may be observed, or conversely, a silly, childlike affect may be seen and manifested by a patient hugging the examiner or giggling after being instructed to stick out his or her tongue or during the testing of the reflexes. Patients with bvFTD may appear obviously restless, standing up and even attempting to leave the room midexamination. Patients with a flat affect may appear apathetic and lack spontaneous speech, giving only brief one-to twoword responses to questions despite preserved language abilities. Although KEY 
I. Neurodegenerative Disease
The following symptom must be present to meet criteria for behavioral variant of frontotemporal dementia (bvFTD).
A. Shows progressive deterioration of behavior and/or cognition by observation or history (as provided by a knowledgeable informant)
II. Possible bvFTD
Three of the following behavioral/cognitive symptoms (AYF) must be present to meet criteria. Ascertainment requires that symptoms be persistent or recurrent, rather than single or rare events. may appear restless, apathetic, perseverative, confabulatory, and impulsive, failing to wait for the examiner to finish task instructions and including expletives in phonemic fluency tests. 8 
Neuroimaging Characteristics
Atrophy or hypometabolism of the right frontal or right temporal lobe is the hallmark neuroimaging finding in patients with bvFTD (Case 5-1). Bilateral frontal lobe involvement may also be seen, although when atrophy is observed in the dominant hemisphere, language symptoms are typically also present (see later discussion of semantic variant PPA and nonfluent agrammatic variant PPA). Patterns of atrophy in other brain regions vary according to mutation type. Patients with C9ORF72 expanded repeats demonstrate atrophy predominantly in the frontal lobes, with some atrophy also observed in the anterior temporal lobes, parietal lobes, occipital lobes, and cerebellum and thalamus; in MAPT mutations, atrophy is greatest in the anteromedial temporal lobes; patients with bvFTD and GRN mutations show temporal, insular, and parietal lobe atrophy. 10, 11 On fluorodeoxyglucose positron emission tomography (FDG-PET) imaging, hypometabolism in the right temporal or right or bilateral frontal lobes is suggestive of FTD ( Figure 5-2 12 ). Patterns of frontal or anterior temporal hypoperfusion with preserved parietal signal on SPECT can distinguish FTD from AD with a sensitivity and specificity of approximately 80%. 13 Similar patterns of hypometabolism on FDG-PET imaging show approximately 90% diagnostic accuracy when distinguishing FTD from AD. 14 
PET amyloid imaging shows a similarly high accuracy of
Case 5-1 A 54-year-old man presented to the psychiatric emergency department for bizarre behavior, claiming he had won the lottery. The family reported that 6 years prior to presentation he became less organized managing his finances. The family discovered 3 years ago that bills, including the mortgage, were going unpaid, and he had accumulated significant credit card debt. His affect became flat, and his family reported that it was ''hard to get a reaction out of him.'' He began to cook in an impulsive way, turning the burners on maximum for everything. The patient had lost his job for inappropriate borrowing of money from clients 1 year prior to presentation. He began buying multiple lottery tickets each week, and despite financial difficulties, he purchased a luxury motorcycle. He began wearing the same clothing multiple days in a row and required encouragement to shower. He lost interest in his hobbies and spent increasing amounts of time ''staring'' at the television. Family history was negative for any neurodegenerative diseases, although his father died in his forties of a myocardial infarction, and his mother died in her early sixties of cancer. On examination, the patient was mildly unkempt, with a flat affect, and appeared apathetic. His speech was fluent with preserved naming, repetition, and comprehension. Cranial nerves were intact, including normal saccades. There was no evidence of bradykinesia. Sensory and motor examinations were normal. He had mild difficulty performing the Luria hand sequence (a three-step hand movement sequence of fist-side-flat) on the left compared to the right. Snout and grasp reflexes were absent (normal). On cognitive testing, he 
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distinguishing FTD from AD, with patients with FTD typically showing low levels of amyloid binding on PET (amyloid negative), while patients with AD show elevated amyloid binding (amyloid positive). 12 Several PET tau ligands are currently under investigation in FTD but are not validated to date.
Diagnostic Challenges in Behavioral Variant of Frontotemporal Dementia
Making and confirming a diagnosis of bvFTD can be challenging as the personality or behavioral changes are insidious, and diagnosis in the early stages is highly reliant on caregiver reports of behavioral changes. Furthermore, the degree of frontal atrophy can overlap with that observed in normal controls. 15 The term bvFTD phenocopy syndrome has been used to characterize patients who present with a history obtained from a caregiver that meets symptom-based criteria for possible FTD but who lack focal atrophy on neuroimaging and who do not progress to demonstrate objective behavioral or cognitive deficits. 16 Patients with bvFTD phenocopy syndrome who fail to progress have increased rates of mood disorders, substance abuse, obsessive-compulsive personality traits, Asperger syndrome traits, or recent intense life events that likely contribute to the observed behaviors. 17 Comment. There is commonly a long delay between the onset of symptoms and time of presentation, given the subtle nature of the personality and behavior changes that are the hallmark of early FTD. Patients often accumulate significant debt prior to diagnosis. It is important for caregivers to put a power of attorney in place for care and finances to limit patients' access to spending money. In patients with frontal lobe deficits, inattention and impulsivity pose significant risks during driving and typically are indications for driving cessation. While there are no treatments specifically approved for use in patients with FTD, off-label use of selective serotonin reuptake inhibitors (SSRIs) may help with agitation, obsessive-compulsive behaviors, and hyperphagia. 9 Continued from page 468 dementia, is the loss of word meaning. 19 Due to atrophy in the dominant anterior temporal pole (Case 5-2), patients with semantic variant PPA demonstrate anomia and single-word comprehension deficits and may ask what words mean (ie, ''What is spaghetti?''). While fluency and grammar are generally maintained, speech becomes increasingly empty, with vague words or jargon phrases replacing specific nouns and verbs ( Table 5- B 2011 American Academy of Neurology.
Case 5-2
A 69-year-old right-handed retired secretary was referred for a neurologic consultation for difficulties with ''memory'' and behavior. She had a long history of anxiety and depression that had been managed by medications until 2 years prior to presentation, when she was dismissed from her volunteer job for ''lacking control.'' Her family noted trouble with word comprehension, as the patient would ask, ''What is a screwdriver?'' and ''What is a buffet?'' Circumlocutions were noted in her descriptions, such as describing a pizza as a ''round thing.'' This was followed by lack of recognition of objects. For example, when her husband handed her an ice cream cone, she grabbed at the ice cream on top rather than from the cone. Recently, she had not recognized her niece and nephew or herself in photographs. The patient stopped initiating household chores, such as doing the dishes or laundry, and appeared confused when attempting such tasks. According to her husband, she was ''always walking, pacing, or standing.'' She became very self-centered and seemed to lack appreciation of others' needs. She became fixated on daily routines
Continued on page 471 even if inconvenient to others. Her personal hygiene declined. Family history was notable for multiple family members on her mother's side with anxiety and depression. There was no known history of neurodegenerative dementia or amyotrophic lateral sclerosis in any family members. On examination, while her speech rate was generally high, she used frequent fillers, such as ''thing'' or ''da da da.'' Her responses to direct questions were tangential. The remainder of her neurologic examination was normal, including the absence of frontal release signs. On further cognitive testing, she scored 8 out of 30 on the Mini-Mental State Examination (MMSE), typically not understanding the question being asked. Her clock drawing skills were reasonably preserved. Semantic fluency was severely impaired with only two animals named in 1 minute. In contrast, phonemic fluency was only mildly impaired with a total of 20 F-A-S Test words named over the 3 minutes (patient was given 1 minute to list words beginning with the letter F, followed by 1 minute to list words beginning with A, and then 1 minute to list words beginning with the letter S). Naming on the Western Aphasia Battery was impaired, with only 11 out of 20 items correct and some evidence of visual object agnosia, including nonrecognition of a pipe. Deficits in semantic association were also demonstrated on the Pyramid and Palm Trees Test. Trail Making B test was normal at the 50th percentile.
Review of a recently performed brain MRI demonstrated severe anterior left temporal lobe atrophy and moderate atrophy of the right temporal pole ( Figure 5-3) . A diagnosis of semantic variant primary progressive aphasia was made.
Comment. This patient demonstrates a classic presentation of semantic variant primary progressive aphasia. Often, the family members may identify the chief complaint as memory deficits, but with careful assessment, it is clear that loss of word meaning and comprehension deficits underlie the observed changes. Behavioral features are usually present early on and progress with increasing atrophy of the right temporal lobe. 
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Patients with semantic variant PPA may lose the normal give and take of conversation, talking incessantly and requiring interruption to conduct the examination. Patients with semantic variant PPA also demonstrate abnormal behaviors, largely overlapping with those described above for patients with bvFTD, likely due to involvement of the right anterior temporal lobe and connections to the orbitofrontal cortex. 21, 22 Patients with right-sided temporal atrophy may present with behavioral features and relatively preserved language, but over time will also develop semantic deficits. As the disease progresses and begins to involve the posterior temporal regions and visual temporal association areas, patients may also develop visual agnosia and prosopagnosia.
Neuropsychological Testing in Semantic Variant Primary Progressive Aphasia
Patients with semantic variant PPA demonstrate deficits in single-word comprehension when asked to define single words (eg, ''What is an accordion?''). Speech production during picture descriptions (ie, cookie jar theft picture) shows a normal or near-normal word production rate but frequent use of filler words (Case 5-2). Tests of seman-tic associations, such as the palms and pyramids task, show deficits for words, and over time, often for picture stimuli. (In the palms and pyramids task, patients are shown a stimulus [a picture or word] and must choose the related picture or word from two choices; eg, a vest is shown with choices of a bowtie [correct] and necklace [incorrect]). Patients with semantic variant PPA may show an interesting pattern of episodic memory deficits opposite to that observed in AD, with better recall of recent events and people and relative loss of more remote autobiographic memories. 23 
Neurologic Examination
Loquacious but empty, tangential, or repetitive speech is evident during the course of the interview and examination. Patients may repeat short catch phrases or jokes. The remainder of the neurologic examination, including frontal reflexes, is typically normal.
Neuroimaging
Atrophy of the dominant anterior temporal pole is the hallmark finding in semantic variant PPA ( Figure 5-3) . 24 While involvement is typically asymmetric at onset, over time the contralateral temporal lobe is also affected. 
Neurologic Examination
Nonfluent speech with word-finding difficulties, circumlocutions, stuttering, and grammatical errors with relative preservation of comprehension is typically observed, although deficits may be mild at first. Subtle right-side motor deficits (slower fine motor movements, pronator drift) may be observed in some patients with more widespread pathology in the left (or dominant) frontal lobe.
Neuroimaging
Nonfluent agrammatic variant PPA is associated with atrophy of the dominant inferior frontal lobe ( Figure 5-4 ).
PROGRESSIVE SUPRANUCLEAR PALSY
Although originally classified as a Parkinson-plus syndrome, PSP is now also included as an FTD-related disorder based on the presence of frontal lobe involvement and tau pathology.
Prior to the onset of hallmark features including early postural instability and vertical gaze impairments, approximately 20% of patients with PSP first present with FTD symptoms, including behavioral changes or progressive language deficits ( 
Case 5-3
A 66-year-old woman presented for a neurologic consultation because of difficulty speaking. She reported 2 to 3 years of gradually increasing deficits in ''getting the words out.'' She stated, ''I know what I want to say, but the words get stuck at the tip of my tongue.'' Her spouse noticed that at times she would get part of the sound of the word correct, and part wrong, such as calling a ''fork'' a ''fort.'' She had also developed a mild stutter. Her husband noticed she was often able to describe the meaning of the word, even when she could not say the word itself. On examination, she demonstrated halting, hesitant speech although she could generally answer questions appropriately. She correctly named a chair and key, but could not name the glove, instead gesturing to her hand. She could not name cactus, but said ''it is a thing that growsIdesertIouch.'' During repetition she omitted small words and made paraphasic errors. She followed all verbal and written commands. When asked to write a sentence, she wrote, ''Today very sunny outside.'' When asked to describe the picnic scene from the Western Aphasia Battery, she demonstrated word-finding deficits, paraphasic errors, and hesitations (item she was pointing to in parentheses): ''The carpet, and man, and womanIon their black (blanket). Man's foodIfood there (sandals). The manIbagIbark (book). The man glass (glasses). Bag (basket). Boy has a kiteIa gagsI(dog). GirlIsongIsandImake (rake), sarvs (shovels), cakeIcast (castle). Man on dark (dock) and fish. Sailboat and two babli (people)Ithere. A house there. A carI garange (garage) there and flangs (flag). Tree.'' The remainder of her neurologic examination was unremarkable. Neuroimaging demonstrated atrophy in the left inferior frontal lobe ( Figure 5-4) . 
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disinhibition, anxiety, dysphoria, stereotypic or repetitive behaviors, and up to 30% of patients with PSP will meet criteria for bvFTD. 26, 27 Patients with PSP may also present with primary apraxia of speech, combined apraxia of speech and progressive nonfluent aphasia, or develop these symptoms One year later, the patient presented with further deficits in articulatory speech consistent with verbal apraxia. She also demonstrated worsening short-term verbal memory deficits and new difficulty with dressing (despite normal strength). On examination, mild rigidity and odd involuntary posturing of her right arm were noted, with ideomotor apraxia and deterioration of handwriting ( Figure 5-5 ).
Comment. This patient initially presented with symptoms meeting criteria for nonfluent agrammatic variant primary progressive aphasia and indicative of dominant frontal lobe pathology. Over time, her symptoms progressed to include apraxia and alien limb phenomenon, consistent with evolution to corticobasal syndrome. In addition to progression to corticobasal syndrome, patients presenting with nonfluent agrammatic variant primary progressive aphasia may also develop symptoms consistent with behavioral variant of frontotemporal dementia or progressive supranuclear palsy. Continued from page 474 during the disease course. 25 In patients presenting with primary apraxia of speech, atrophy or hypometabolism is found in the superior premotor cortex and supplementary motor area, and PSP is the most common underlying pathology. 28 
Neurologic Examination
In the most common subtype of PSP, Richardson syndrome, increased axial rigidity of the neck and trunk, slowed vertical saccades, dysarthria, apathy or depression, and general slowing of speech and thought are observed. 26 Gait is often narrow based in early stages of the disease despite a history of falls and imbalance. As the disease progresses, patients often develop ophthalmoplegia particularly of vertical gaze, akinetic rigid parkinsonism, dystonia, verbal apraxia, pseudobulbar palsy, and frontal release signs.
Neuropsychological Testing
Cognitive deficits are found in the majority of patients with PSP. Most commonly, patients with PSP demonstrate cognitive slowing and poorer performance on timed tests of executive function and verbal fluency. 27 Comprehension and memory are generally preserved.
Neuroimaging
Structural imaging in PSP may reveal midbrain atrophy referred to as the hummingbird sign on sagittal images ( Figure 5-6 29 ), as well as hypometabolism in frontal, caudate, midbrain, and thalamic regions on FDG-PET. 30 
CORTICOBASAL DEGENERATION
Corticobasal degeneration (CBD) is a progressive neurodegenerative disorder affecting the frontal and parietal cortices and basal ganglia associated with abnormal 4-repeat tau isoform pathology. The term corticobasal syndrome (CBS) is used to describe patients presenting with the clinical features associated with CBD but who lack histologic confirmation, as CBS presentations may be associated with a variety of underlying neuropathologies including AD, FTD, and CBD. CBD is typically sporadic, although occasionally CBS is the presenting phenotype for patients with MAPT, GRN, or C9ORF72 mutations. Classic features of CBS include apraxia and alien limb phenomenon, frontal deficits, and extrapyramidal motor symptoms such as myoclonus or rigidity. Five phenotypic presentations of CBD have recently been proposed ( lobes, including apraxias and visuospatial deficits, may also be a presenting feature. 32 Motor abnormalities may be absent in as many as approximately 50% of patients at the time of presentation with cognitive deficits, although during the course of the disease the majority of patients will show motor features. Approximately 30% of patients with CBS will develop alien limb syndrome, in which one arm may levitate or assume involuntary postures or movements, and 25% will have cortical sensory deficits. 31
Neurologic Examination
Patients presenting with frontal or aphasic subtypes of CBS may present with inappropriate behavioral features described above for bvFTD, or language deficits consistent with nonfluent agrammatic variant PPA, or apraxia of speech. Asymmetric limb rigidity and bradykinesia are the most common motor findings, present in approximately 50% of patients at the time of presentation. 31 Ideomotor apraxia is a frequent finding and may also be asymmetric. Other motor features can include tremor, postural instability and falls, axial rigidity, dystonia including blepharospasm, alien limb, and myoclonus. Cortical sensory deficits may include sensory extinction, agraphesthesia, and astereognosia.
Neuropsychological Testing
Performance patterns on cognitive testing may vary according to the subtype. Many patients with CBS will demonstrate deficits on tasks of executive function, writing, visuospatial, and construction tasks ( Figure 5-5 ). Patients presenting with dominant frontal lobe involvement may show wordfinding deficits, agrammatism, and spelling errors similar to patients with nonfluent agrammatic PPA. 32 Neuroimaging Structural brain imaging in patients with CBS may show asymmetric frontal and parietal lobe atrophy, 33 although imaging findings may overlap with those seen in other FTDs and AD. Thus, diagnosis at present is based on clinical criteria, with neuroimaging performed to rule out other structural causes of symptoms.
FRONTOTEMPORAL DEMENTIAYMOTOR NEURON DISEASE
Frontotemporal dementia symptoms are found in approximately 30% of patients diagnosed with amyotrophic lateral sclerosis (ALS). Patients with FTD-ALS may present with behavioral changes consistent with bvFTD or a milder dysexecutive profile including verbal fluency deficits. 34 Hallucinations and delusions are more common in patients with FTD-ALS, in particular in patients with C9ORF72 expanded repeat mutations (see the following section on genetic risk factors), the most common genetic cause of familial FTD-ALS. 35, 36 
PROGNOSIS
The average survival for patients diagnosed with FTD is approximately 7 to 10 years. Estimates differ somewhat according to FTD subtype, with survival in FTD-MND averaging just 2 to 3 years, approximately 6 to 8 years in PSP, approximately 9 to 10 years in bvFTD and nonfluent agrammatic variant PPA, and the longest median survival in patients with semantic variant PPA of approximately 12 years. 2 Common proximate causes of death in patients with FTD related to the disease include pneumonia or complications of falls.
RISK FACTORS
Although approximately 50% to 60% of FTD is considered to be sporadic in etiology, genetic mutations account for the majority of risk factors identified for developing FTD.
Environmental
To date there have been few studies of environmental risk factors for FTD. Retrospective case-control studies have found an increased incidence of head injury in patients with a clinical diagnosis of FTD (odds ratios of 3 to 4). 37, 38 While repetitive concussions have been linked to progressive neuropsychiatric symptoms, cognitive deficits, and pathologic tau deposition in the frontal and temporal lobes in chronic traumatic encephalopathy, 39 the relationship of isolated concussion or mild head injury in relation to chronic traumatic encephalopathy and other forms of FTD is not yet understood.
Genetic
Approximately 40% of FTD is associated with an autosomal dominant pattern of inheritance, with remaining cases considered sporadic. 40 A careful family history considering not only diagnosis, but also possible FTD symptoms in other family members is essential, as FTD was rarely diagnosed before the 1990s, and family members may have been misdiagnosed with AD, vascular dementia, or late-onset psychiatric disorders. bvFTD and nonfluent agrammatic variant PPA are the most common phenotypes in genetic FTD, although CBS presentations can also occur. Semantic variant PPA is almost always sporadic. PSP is not associated with the FTD mutations described below, although is linked to the H1 haplotype in the MAPT gene (see Box 1 Glossary of Gene and Protein Abbreviations). Mutations in approximately eight genes have been linked to FTD, accounting for approximately 50% of familial FTD, with mutations in GRN, C9ORF72, and MAPT accounting for the majority of cases of genetically confirmed FTD ( Table 5- 6 35,36,41Y53 ). 41 Several other genetic mutations are known to be rare causes of familial FTD, including mutations in the CHMP2B gene encoding charged multivesicular body protein 2B and mutations in the gene for valosin-containing protein (VCP), which is associated with the clinical triad of FTD, inclusion body myopathy, and Paget disease. Of interest, variants in the gene for transmembrane protein 106B (TMEM106B) have been identified to confer protection and delay onset of FTD in patients with GRN and C9ORF72 mutations. 54 A genetic mutation may be found in approximately 6% of patients with no family history of FTD; thus, referral to a genetic counselor for consideration of genetic testing may be considered for all patients presenting with FTD. 55 NEUROPATHOLOGY Abnormal accumulations of tau or TDP-43 account for the majority of pathologically confirmed cases of FTD, with FUS inclusions most common in the remaining 10% ( Figure 5-7 56 ). 55 Abnormal aggregations of tau can be found in patients with sporadic bvFTD, CBS, nonfluent agrammatic variant PPA, and PSP as well as MAPT-associated familial FTD ( Figure 5-8 inclusions account for the majority of the remaining tau-negative patients. TDP-43 pathology is found in patients with semantic variant PPA, FTD-MND, and bvFTD, as well as in genetic variants including C9ORF72, GRN, and VCP mutations. TDP-43 pathology is characterized by four patterns that show associations with FTD clinical phenotypes ( Figure 5-9 57 ). FUS pathology is associated with an earlier age of onset of FTD, prominent neuropsychiatric features, and a more rapid course. 55 It has been hypothesized that von Economo neurons, large bipolar neurons in layer V of the cortex, in the anterior cingulate region and frontoinsular junction may be the first site of disease pathology, as early loss of these neurons is found in patients with FTD compared to AD and controls. 58 
CEREBROSPINAL FLUID AND SERUM BIOMARKERS
At present, CSF biomarkers may help to distinguish between FTD and AD, but there are no validated biomarkers that can reliably distinguish patients with FTD from controls or other non-AD dementias. The presence of an AD pattern of biomarkers is considered an exclusion criterion for probable FTD. 4 CSF biomarkers demonstrating imaging or CSF A" and tau analysis may aid in distinguishing FTD from frontal or language presentations of AD. For patients interested in genetic testing, or those with a family history suggestive of FTD or ALS, referral to a genetic counselor for consideration of genetic testing is indicated. Knowledge of genetic status can confirm a diagnosis of familial FTD and may aid referral of patients and carriers to current and future clinical trials targeting specific FTD mutations.
PATIENT MANAGEMENT
There are currently no therapies specifically approved for FTD. Thus, education and supportive management of safety and behavioral issues for the patient and caregiver are essential in supporting patients with FTD. 64, 65 Supportive Management and Follow-up Assessments A power of attorney for personal care and finances should be put into place for patients with FTD, as impaired judgment and impulsivity can result in significant financial difficulties. There are few studies of driving safety in patients with FTD. Those available suggest that the risk of accidents is increased even in patients with mild disease and is related to inattention, impulsivity, and poor emotion regulation. Careful and frequent reassessment of patient's behavioral symptoms and cognitive testing performance when considering driving privileges is necessary, potentially supported by onroad driving assessments. Caregivers and families should also be counseled regarding gun safety or other potentially hazardous activities or pastimes. Speech and swallowing assessments are indicated to optimize communication strategies and screen for dysphagia, which is common, particularly in patients with nonfluent agrammatic variant PPA and PSP. Physical therapy evaluations of gait when falls or balance problems are reported and occupational therapy assessments of home safety are also indicated. Caregivers should be referred to local FTD or dementia support groups for support and education of behavioral management strategies. The changes in behavior chart offers helpful strategies for problematic behaviors (www.theaftd.org/ wp-content/uploads/2011/09/Packet-Changes-in-behavior-chart.pdf ). 66 
Pharmacologic Treatment
Current treatment approaches are limited to symptomatic treatments that employ off-label uses of medications modulating neurotransmitter systems, usually to modify difficult behaviors. 9, 67 Most commonly, selective serotonin reuptake inhibitors (SSRIs), such as citalopram, or trazodone are used to improve behavioral symptoms including disinhibition, agitation/irritability, or compulsive behaviors (Table 5-7 9,68Y75 ). Psychosis and aggression may require neuroleptic medications, although gold standard randomized clinical trials of these agents are not available in patients with FTD. If needed, initiation at a low dose and frequent reassessment of efficacy and need for continued use are required given black box warnings for this class of medications due to increased mortality. Although parkinsonism in patients with FTD is usually not dopamine responsive, as a fraction of patients may benefit, a trial of carbidopa/levodopa titrating up to 25 mg/250 mg 3 times daily for parkinsonism is generally indicated. Cholinesterase inhibitors may frequently increase agitation in patients with bvFTD and, thus, are not indicated.
For patients with CBS or nonfluent agrammatic variant PPA who have memory deficits, approximately 30% to 40% may have underlying AD pathology, and therefore a 2-to 3-month trial of a cholinesterase inhibitor is warranted. A double-blind, placebocontrolled randomized trial of memantine for cognitive and behavioral symptoms of FTD showed no benefit. 76 Clinical trials of novel agents targeting specific genes, related proteins and pathways for tau, progranulin, and C9ORF72 are anticipated in the near future.
CONCLUSION
The FTDs can be recognized based on careful parsing of clinical features and neuroimaging characteristics. Consideration of referral for genetic counseling and genetic testing is indicated for most patients given the high incidence of hereditary FTD.
Although not yet widely available for clinical use, molecular-specific diagnostic tools (eg, tau PET imaging, TDP-43 and tau biomarkers) and treatments are under development, making accurate recognition and diagnosis of FTD and FTD subtype essential for appropriate counseling and management.
